Mahendran G, Shangaradas A, Romero-Moreno R, Wickramarachchige Dona N, Sarasija S, Perera S
Front Oncol. 2025; 14:1499950.
PMID: 39744000
PMC: 11688480.
DOI: 10.3389/fonc.2024.1499950.
Kang J, Lee Y, Kim D, Kim J, Cheon M, Lee B
Commun Biol. 2024; 7(1):1289.
PMID: 39384879
PMC: 11464688.
DOI: 10.1038/s42003-024-06995-9.
Tinglin J, McLeod M, Williams C, Tipre M, Rocque G, Crouse A
J Racial Ethn Health Disparities. 2024; .
PMID: 39235712
PMC: 11880353.
DOI: 10.1007/s40615-024-02104-y.
Chaudhry Z, Boyadzhyan A, Sasaninia K, Rai V
Antibodies (Basel). 2024; 13(2).
PMID: 38920970
PMC: 11200483.
DOI: 10.3390/antib13020046.
Ahmad H, Ali A, Khalil A, Ali R, Khan I, Khan M
Front Genet. 2024; 15:1383284.
PMID: 38784039
PMC: 11111998.
DOI: 10.3389/fgene.2024.1383284.
Breast Cancer Polygenic Risk Score Validation and Effects of Variable Imputation.
Beck J, Slunecka J, Johnson B, Van Asselt A, Finnicum C, Ageton C
Cancers (Basel). 2024; 16(8).
PMID: 38672660
PMC: 11048743.
DOI: 10.3390/cancers16081578.
Radiosensitizing effect of a novel CTSS inhibitor by enhancing BRCA1 protein stability in triple-negative breast cancer cells.
Choi E, Jeon K, Lee H, Mun G, Kim J, Shin J
Cancer Sci. 2024; 115(6):2036-2048.
PMID: 38613358
PMC: 11145138.
DOI: 10.1111/cas.16174.
Carrying SNP rs17506395 (T > G) in gene and CCR5Δ32 mutation associated with the occurrence of breast cancer in Burkina Faso.
Traore L, Savadogo M, Zoure A, Kiendrebeogo T, Soudre F, Dabre S
Open Life Sci. 2024; 19(1):20220847.
PMID: 38585642
PMC: 10998675.
DOI: 10.1515/biol-2022-0847.
Preliminary insights on the mutational spectrum of BRCA1 and BRCA2 genes in Pakhtun ethnicity breast cancer patients from Khyber Pakhtunkhwa (KP), Pakistan.
Ahmad H, Ali A, Ali R, Khalil A, Khan I, Khan M
Neoplasia. 2024; 51:100989.
PMID: 38537553
PMC: 11026844.
DOI: 10.1016/j.neo.2024.100989.
The Impact of microRNA SNPs on Breast Cancer: Potential Biomarkers for Disease Detection.
Chauhan S, Mathur R, Jha A
Mol Biotechnol. 2024; 67(3):845-861.
PMID: 38512426
DOI: 10.1007/s12033-024-01113-w.
Economic evaluation of germline genetic testing for breast cancer in low- and middle-income countries: a systematic review.
Goh S, Ong S, Chan J
BMC Cancer. 2024; 24(1):316.
PMID: 38454347
PMC: 10919043.
DOI: 10.1186/s12885-024-12038-7.
Unveiling pathogenic mutations in BRCA1 and BRCA2 genes across head and neck squamous cell carcinoma patients via next generation sequencing.
Wei X, Tian Z, Zhao F, Sun A, Zhao S, Jamil M
Am J Cancer Res. 2024; 13(12):6099-6112.
PMID: 38187047
PMC: 10767334.
.
Rosado-Jimenez L, Mestre-Terkemani Y, Garcia-Aliaga A, Marin-Vera M, Macias-Cerrolaza J, Sarabia-Meseguer M
Adv Lab Med. 2023; 4(3):288-297.
PMID: 38075173
PMC: 10701495.
DOI: 10.1515/almed-2023-0032.
Recurrent genetic variants and prioritization of variants of uncertain clinical significance associated with hereditary breast and ovarian cancer in families from the Region of Murcia.
Rosado-Jimenez L, Mestre-Terkemani Y, Garcia-Aliaga A, Marin-Vera M, Macias-Cerrolaza J, Sarabia-Meseguer M
Adv Lab Med. 2023; 4(3):279-287.
PMID: 38075165
PMC: 10701504.
DOI: 10.1515/almed-2023-0103.
SGLT2 Inhibitor Use and Risk of Breast Cancer Among Adult Women with Type 2 Diabetes.
Wang F, Hendryx M, Liu N, Bidulescu A, Mitra A, Luo J
Drug Saf. 2023; 47(2):125-133.
PMID: 38070101
DOI: 10.1007/s40264-023-01373-6.
Mutational Landscape and In-Silico Analysis of , , and in Patients with Breast Cancer from Khyber Pakhtunkhwa.
Ahmad H, Ali A, Ali R, Khalil A, Khan I, Khan M
ACS Omega. 2023; 8(45):43318-43331.
PMID: 38024667
PMC: 10652387.
DOI: 10.1021/acsomega.3c07472.
Only 32.3% of Breast Cancer Families with Pathogenic Variants in Cancer Genes Utilized Cascade Genetic Testing.
Agiannitopoulos K, Potska K, Katseli A, Ntogka C, Tsaousis G, Pepe G
Cancers (Basel). 2023; 15(21).
PMID: 37958392
PMC: 10649031.
DOI: 10.3390/cancers15215218.
Family and personal history of cancer in the All of Us research program for precision medicine.
Keeler Bruce L, Paul P, Kim K, Kim J, Keegan T, Hiatt R
PLoS One. 2023; 18(7):e0288496.
PMID: 37459328
PMC: 10351738.
DOI: 10.1371/journal.pone.0288496.
Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
Litton J, Beck J, Jones J, Andersen J, Blum J, Mina L
Oncologist. 2023; 28(10):845-855.
PMID: 37318349
PMC: 10546823.
DOI: 10.1093/oncolo/oyad139.
What Is Known about Breast Cancer in Young Women?.
Zhu J, Charkhchi P, Adekunte S, Akbari M
Cancers (Basel). 2023; 15(6).
PMID: 36980802
PMC: 10047861.
DOI: 10.3390/cancers15061917.